Moreover, the IDH1 inhibitor ivosidenib has been shown to improve progression-free survival in pretreated IDH1-mutated CCA in comparison to placebo in the ClarIDHy phase 3 trial (NCT02989857) [12]. Here, IDH1 is linked to cholangiocarcinoma.